BIOMARIN PHARMACEUTICAL INC Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 9.28 million shares for the 3-month period ending 2014-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2015-11-02
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2014-09-30 was 9.28M shares.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2013-09-30 was 0.00 shares.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2011-09-30 was 16.67M shares, a 22.96% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2011-06-30 was 17.44M shares, a 8.70% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2012 was 0.00 shares.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2011 was 0.00 shares, a 100.00% decline from fiscal 2010.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2010 was 2.40M shares.
- BIOMARIN PHARMACEUTICAL INC incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2009 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2014-09-30 | 9.28M shares 10-Q · filed 2015-11-02 | 0.00 shares 10-Q · filed 2014-10-28 | ||
| 2013-09-30 | 0.00 shares 10-Q · filed 2014-10-28 | 0.00 shares 10-Q · filed 2014-10-28 | ||
| 2012-12-31 | 0.00 shares 10-K · filed 2013-02-26 | |||
| 2011-12-31 | 0.00 shares 10-K · filed 2013-02-26 | |||
| 2011-09-30 | 16.67M shares 10-Q · filed 2011-10-31 | 16.67M shares 10-Q · filed 2011-10-31 | ||
| 2011-06-30 | 17.44M shares 10-Q · filed 2011-08-01 | 17.44M shares 10-Q · filed 2011-08-01 | ||
| 2010-12-31 | 2.40M shares 10-K · filed 2013-02-26 | |||
| 2010-09-30 | 13.56M shares 10-Q · filed 2011-10-31 | 13.57M shares 10-Q · filed 2011-10-31 | ||
| 2010-06-30 | 16.05M shares 10-Q · filed 2011-08-01 | 13.89M shares 10-Q · filed 2011-08-01 | ||
| 2009-12-31 | 0.00 shares 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |